5 recruiting, 2 active not recruiting, 2 completed, 1 suspended. 9 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 5, Active not recruiting 2, Completed 1, Suspended 1 |
| Phase 1 | 3 | Completed 1, Recruiting 1, Suspended 1 |
Follow Refractory Primary Mediastinal Large B-Cell Lymphoma: new trials by email Literature Review of Refractory Primary Mediastinal Large B-Cell Lymphoma trials Research Report on Refractory Primary Mediastinal Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Biopsy Procedure, Biospecimen Collection - Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | City of Hope Medical Center | 43 | 2026-07-27 | 2026-08-28 |
| ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Suspended | Fred Hutchinson Cancer Center | 33 | 2025-12-27 | 2026-09-11 |
| Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T Odronextamab, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of Washington | 27 | 2025-09-04 | 2026-08-28 |
| Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma | Phase 1 / Phase 2 | Recruiting | Yazeed Sawalha | 38 | 2025-04-02 | 2026-08-25 |
| Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 2 | Recruiting | Mayo Clinic | 41 | 2025-04-02 | 2026-10-20 |
| Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse golcadomide - Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma | Phase 2 | Recruiting | The Lymphoma Academic Research Organisation | 65 | 2024-06-14 | 2026-06-04 |
| TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Ontorpacept - Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | Mayo Clinic | 10 | 2023-04-19 | 2026-04-22 |
| NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Completed | Fred Hutchinson Cancer Center | 27 | 2022-12-08 | 2026-09-21 |
| Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma Copanlisib Hydrochloride, Nivolumab - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2019-12-13 | 2025-03-03 |
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Nivolumab, Varlilumab - ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2018-12-21 | 2026-10-26 |
Lymphoma, Large B-Cell, Diffuse (9) · Lymphoma, B-Cell (2) · Burkitt Lymphoma (1) · Lymphoma, Primary Effusion (1) · Lymphomatoid Granulomatosis (1) · Plasmablastic Lymphoma (1)
Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphatic Diseases (9) · Lymphoma (9) · Lymphoma, Non-Hodgkin (9) · Lymphoproliferative Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Lymphoma, B-Cell (7) · DNA Virus Infections (1) · Epstein-Barr Virus Infections (1) · Herpesviridae Infections (1) · Infections (1) · Precancerous Conditions (1)
Biopsy (7) · Magnetic Resonance Spectroscopy (7) · Specimen Handling (5) · Leukapheresis (3) · Spinal Puncture (3) · CT-P10 (2) · Immunotherapy, Adoptive (2) · Nivolumab (2) · Phantoms, Imaging (2) · Rituximab (2) · X-Rays (2) · Cyclophosphamide (1) · Disulfides (1) · Gemcitabine (1) · Immunoglobulin G (1)
Fred Hutchinson Cancer Center (2) · Mayo Clinic (2) · National Cancer Institute (NCI) (2) · City of Hope Medical Center (1) · The Lymphoma Academic Research Organisation (1) · University of Washington (1) · Yazeed Sawalha (1)
United States (9) · France (1)
Alexandre Hirayama (1) · Alexandre V. Hirayama, MD (1) · Claire Tiger, MD, PhD (1) · Geoffrey Shouse (1) · Mengyang Di, MD, PhD (1) · Nabila N Bennani (1) · Stephen M Ansell (1) · Stephen M. Ansell, MD, PhD (1) · Yazeed Sawalha (1)
UM1CA186686 (2), UM1CA186709 (2), P30CA033572 (1)